I first identified Pfizer as a buy a few months back, noting that that generic availability of its most famous drug, Viagra, was going to have little negative impact of the company’s health, given its extremely robust pipeline. (The company is expecting 25 to 30 key regulatory approvals over the next five years.) Since then, things have been great for the company and the stock, until, beginning last week, shares took a nosedive, falling all the way from $39 and change to under $35. Given that the strength is still there, this could be the perfect time to buy.
Chart courtesy of www.stockcharts.com